FDA Grants RMAT Designation to United Therapeutics' Miroliverelap for Acute Liver Failure
Summary
United Therapeutics has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its investigational product, Miroliverelap®, for the treatment of acute liver failure. This designation is a significant positive development, as it is granted to regenerative medicine therapies intended to treat serious or life-threatening diseases and provides for expedited development and review. The RMAT status underscores the potential of Miroliverelap® to address a critical unmet medical need and could accelerate its path to market, adding to the company's robust pipeline.
At the time of this announcement, UTHR was trading at $559.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.8B. The 52-week trading range was $266.98 to $607.89. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.